IP Library Granted Patent US 8,921,413
Granted Patent B2
US 8,921,413 · App. 14/086,529 · Granted Dec 30, 2014

β- and γ-diketones and γ-hydroxyketones as

Inventors: Sunil Kumar KC (San Diego, CA); David Mark Wallace (San Diego, CA); John Hood (San Diego, CA); Charlene F. Barroga (San Diego, CA)
Assignee: Samumed, LLC
C07D319/18C07C49/784C07D213/50C07D405/06C07D405/10C07D407/10C07D409/06C07D409/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,413
App. No.
14/086,529
Granted
Dec 30, 2014
Kind
B2
Abstract

The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

Claims (35)

1. A method of treating alopecia in a mammal, comprising topically administering to the mammal a therapeutically effective amount of a compound, or pharmaceutically acceptable salt thereof, having the structure of Formula I:

wherein:

R 1 is a substituted or unsubstituted heteroaryl, wherein the heteroaryl is selected from the group consisting of

 with the proviso that a carbon atom of the R 1 heteroaryl is attached to the carbonyl;

R 2 is a substituted or unsubstituted aryl, wherein the aryl is selected from phenyl or naphthyl; and

R 3 , R 4 , R 5 and R 6 are H.

2. The method of claim 1 , wherein R 1 is

3. The method of claim 1 , wherein R 2 is a substituted or unsubstituted phenyl.

4. The method of claim 1 , wherein the compound of Formula I has a structure selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein R 1 is

and R 2 is a substituted or unsubstituted phenyl.

6. The method of claim 5 , wherein the compound of Formula I is:

or a pharmaceutically acceptable salt thereof.

7. The method of claim 5 , wherein the compound of Formula I is:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 5 , wherein the compound of Formula I is:

or a pharmaceutically acceptable salt thereof.

9. A method of treating alopecia in a mammal, comprising topically administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula I:

wherein:

R 1 is a substituted or unsubstituted heteroaryl, wherein the heteroaryl is selected from the group consisting of

 with the proviso that a carbon atom of the R 1 heteroaryl is attached to the carbonyl;

R 2 is a substituted or unsubstituted aryl, wherein the aryl is selected from phenyl or naphthyl; and

R 3 , R 4 , R 5 and R 6 are H;

and a pharmaceutically acceptable excipient.

10. The method of claim 9 , wherein R 1 is

11. The method of claim 9 , wherein R 2 is a substituted or unsubstituted phenyl.

12. The method of claim 9 , wherein the compound of Formula I has a structure selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

13. The method of claim 9 , wherein the compound of Formula I is:

or a pharmaceutically acceptable salt thereof.

14. The method of claim 9 , wherein the compound of Formula I is:

or a pharmaceutically acceptable salt thereof.

15. The method of claim 9 , wherein the compound of Formula I is:

or a pharmaceutically acceptable salt thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 12, 2026
From: TMF GROUP NEW YORK, LLC, NOT INDIVIDUALLY BUT SOLELY AS COLLATERAL AGENT
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 075109/0434 →
SECURITY INTEREST Recorded Sep 14, 2022
From: BIOSPLICE THERAPEUTICS, INC.
To: VICKERS VENTURE FUND VI PTE. LTD.; VICKERS VENTURE FUND VI (PLAN) PTE. LTD.; VICKERS-SPLICE CO-INVESTMENT LLC; MED-PATHWAYS II LIMITED
Reel/Frame 061433/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2021
From: SAMUMED, LLC
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 055693/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2013
From: KC, SUNIL KUMAR; WALLACE, DAVID MARK; HOOD, JOHN; BARROGA, CHARLENE F.
To: SAMUMED, LLC
Reel/Frame 031780/0868 →
Continuity (4)
Continuation 13211665 · Aug 17, 2011
Provisional Application 61427974 · Dec 29, 2010
Provisional Application 61374687 · Aug 18, 2010
Related Publication 20140080902A1 · Mar 20, 2014